United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eli Lilly

Johnson & Johnson

Capital is flowing once more into healthcare stocks. These companies are three of the best components of the sector for investors to buy now.

3 Healthcare Stocks to Buy as the Sector Breaks Out

Pfizer Inc (NYSE: PFE) has started testing fully vaccinated adults over 65 in a new study exploring the company's 20-valent pneumococcal conjugate vaccine (20vPnC) candidate after a third dose of the Pfizer-BioNTech SE (NASDAQ: BNTX) COVID-19 shot. The primary objective of the trial is to assess safety with a follow-up six months after vaccination.

Pfizer Starts Testing Pneumococcal Vaccine Candidate Along With COVID-19 Booster Shot

Shares of Pfizer Inc. gained 0.1% in premarket trading on Monday after the company said it is testing its experimental 20-valent pneumococcal conjugate vaccine in combination with a booster dose of its COVID-19 vaccine in adults who are 65 years old or older. The study includes 600 participants from the Phase 3 clinical trial for the COVID-19 vaccine.

Pfizer is testing a COVID-19 booster shot in combination with new pneumococcal conjugate vaccine candidate

AstraZeneca

BioNTech SE

In this week's coronavirus (COVID-19) vaccine news, the UK has reached the 60mln milestone of administered doses.  That includes 22mln people having received both shots required to complete the immunisation course.

Coronavirus vaccines: UK hits 60mln doses milestone as new study proves AstraZeneca, Pfizer/BioNTech jabs work against Indian variant

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the first enrolled subjects have received their immunizations as part of a new study in adults ages 65 or older exploring the coadministration of the company's 20-valent pneumococcal conjugate vaccine (20vPnC) candidate following a booster dose of the Pfizer-BioNTech COVID-19 Vaccine, currently authorized by the Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA). The primary objective in the trial

Pfizer Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of the Pfizer-BioNTech COVID-19 Vaccine in Older Adults

A big order is only part of the equation.

3 Reasons Why This Vaccine Maker May Dominate the European Market

Bank of America

Kroger

Microsoft

Uber

Some of the world's most successful money managers piled into these popular stocks during the first quarter.

5 Stocks Billionaires Couldn't Stop Buying in Q1

Pfizer's Q1 earnings showed how immense the Covid vaccination program will be for the company's financials. A tremendous growth runway remains as the US population continues to vaccinate, many international populations remain in need of vaccinations, and booster shots will be required.

Pfizer's New Vaccine Golden Goose Makes It A Buy

Here's why you might want to consider adding this best-in-class stock to your portfolio.

Is Pfizer Stock Still a Top Buy for 2021?

Pfizer Inc (NYSE: PFE) and the Indian government are at loggerheads over a demand by the company for legal protection from any claims linked to the use of its COVID-19 vaccine, said Reuters citing two sources. What Happened: India has not given any manufacturer of a COVID-19 vaccine indemnity against the costs of compensation for any severe side effects.

Pfizer Hits Deadlock With India Over Vaccine Indemnity Issue: Reuters

Pfizer (PFE)/BioNTech (BNTX) have a total supply order for 2.4 billion doses of its COVID-19 vaccine, Comirnaty in Europe.

Pfizer/BioNTech to Supply 1.8B More Doses of Comirnaty in EU

These pharmaceutical sector stocks can be relied on even in troubled times on Wall Street.

2 Blue Chips I'd Love to Buy in a Bear Market

Grayscale Ethereum Mini Trust

Yum China Hlds

Arlington Asset Investment

QUALCOMM

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified Ethan Allen Interiors and Yum China Holdings among the trending stocks.

Artificial Intelligence Identifies Ethan Allen Interiors And Yum China Holdings As Trending Stocks Today

The European Commission has signed a third contract with BioNTech SE (NASDAQ: BNTX) and Pfizer Inc (NYSE: PFE) for an additional 1.8 billion doses of its COVID-19 vaccine, Comirnaty. The contract reserves the doses on behalf of all European Union member states, between the end of 2021 to 2023, the statement added.

European Commission Inks Third Supply Pact With BioNTech-Pfizer For 1.8B Vaccine Doses

Pfizer Inc. and German partner BioNTech SE said Thursday they have reached a new agreement with the European Commission to supply up to 1.8 billion additional doses of their COVID-19 vaccine. The partners said the agreement is to provide 900 million doses initially with an option for the EC to request up an additional 900 million doses.

Pfizer and BioNTech to supply EU with up to 1.8 billion additional COVID vaccine doses

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY®, the companies' COVID-19 vaccine, to the European Union (EU), with an option for the EC to request up to an additional 900 million doses. This new agreement is in addition to the 600 million doses that have already been committed to the EU through 2021. The additional 900 million agreed dose

Pfizer and BioNTech to Supply the European Union With up to 1.8 Billion Additional Doses of COMIRNATY®

Pfizer Inc (NYSE: PFE) will begin producing an essential ingredient for its COVID-19 vaccine developed in partnership with BioNTech SE (NASDAQ: BNTX) at a facility in Ireland. An existing Pfizer facility in Grange Castle, Dublin, will be adapted to produce the "mRNA drug substance," a core component in the vaccine, for $40 million, the Irish Times reported.

Pfizer To Start Making COVID-19 Vaccine Component In Ireland By 2021 End

Moderna

Vaccine makers, including Pfizer, Johnson & Johnson, AstraZeneca, and BioNTech, are set to make billions for many years to come.

Vaccine Makers Will Make Billions For Years To Come: Which One To Buy Now

The biotech came out of nowhere to vault near the top of this survey ranking.

Here's 1 Surprising Ranking Where Moderna Handily Beats Pfizer

The length of time the Pfizer/BioNTech vaccine can be kept unopened in a fridge has been increased from five days to one month.

Pfizer jab can now be stored in a fridge for one month, regulator says

Those plans come after the White House said it would send 60 million doses of AstraZeneca's Covid vaccine to countries in need

Biden to say U.S. will send 20 million Pfizer, Moderna or J&J vaccine doses abroad by end of June

Procter & Gamble

Viatris

Vanguard High Dividend Yield ETF

Verizon

Exxon Mobil

The S&P 500 is now hitting and crossing over 4,200+ and valuation continues to be a struggle in the stock market. My dividend stock portfolio was burnt by dividend cuts in 2020 and lost over $800+ in forward dividend income.

Dividend Stock Purchase: Lanny's April 2021 Summary

Bristol-Myers

Pfizer Inc (NYSE: PFE) and Bristol Myers Squibb Co (NYSE: BMY) partnered Eliquis (apixaban) failed to show benefit over standard of care in preventing serious clinical outcomes after a transaortic valve replacement (TAVR), according to the data from a new trial called Atlantis presented at the virtual American College of Cardiology meeting. The drug was linked to an “unexplained signal” in a subset of populations with a higher rate of non-cardiovascular deaths which did not need blood thinners apart from the surgery.

Pfizer-Bristol Myers' Eliquis Flops In Post-Heart Surgery Trial

TOKYO, May 17, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") will share new data across its oncology portfolio during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8, 2021.

Astellas to Present Data from Expanding Oncology Portfolio During the 2021 ASCO Annual Meeting

There are several variables that will make a key difference.

News for Pfizer Stock (PFE)